CONTINUING EDUCATION


Several ASHP Virtual Symposia continuing education programs are currently being offered HERE
 

New England Cardiology Symposium for Pharmacists
Sheraton· Boston, MA
View the TG MedEd Website

Sept 7th, 2007

REGISTER TODAY!!



The New England Cardiology Symposium for Pharmacists is a comprehensive multidisciplinary overview of major issues concerning heart attack, heart failure, and venous thromboembolism.  State-of-the-art presentations will incorporate perspectives from basic science, clinical research, prevention, treatment, and management.

The course will be presented in multiple formats: 1) lectures, 2) discussion and questions and answers following each lecture, and 3) focused break out sessions on HIT and hyponatremia. The course design is an open and interactive forum.

Participants will receive a comprehensive syllabus and CD ROM that include lecture outlines with slide panels and extensive up-to-date bibliographies.

Click Here for Online Registration

TARGET AUDIENCE

Pharmacists engaged in basic and clinical cardiology research, community pharmacists, and hospital pharmacists who are involved in the care and management of patients’ cardiovascular medication regimens.

TUITION

The cost to attend this program is $65.00.

Massachusetts Society of Health System Pharmacy (MSHP) Members qualify for a reduced tuition of $45.00.

COURSE LOCATION

All sessions will be held at the Sheraton Boston Hotel, Prudential Center, 39 Dalton Street; Boston, Massachusetts 02199 (Telephone: 617-236-2000). To check room availability, please visit: www.Sheraton.com/Boston

NEEDS ASSESSMENT

Cardiovascular disease is the most common cause of death and medical disability in the United States.  Major cardiovascular conditions include acute coronary syndromes (i.e., unstable angina and myocardial infarction), heart failure, stroke, and venous thromboembolism.  Despite the high incidence of cardiovascular events, many pharmacists are not up to date with identification and current management of cardiovascular disease.  Pharmacists are often the first line for questions from clinicians regarding therapies for patients at risk or experiencing cardiovascular disorders, or the educator of patients upon receiving their medication.

Over the past decade, pharmacy education and practice has developed a strong commitment to making the best use of available medications.  As the role of the pharmacist evolves and becomes more focused on pharmaceutical care, there is a greater need for pharmacist understanding of drug therapy and current management of the individual patient’s needs.

The “New England Cardiology Symposium for Pharmacists,” to be held Friday, September 7, 2007, in Boston, Massachusetts, has been conceptualized to fill a void that currently exists in cardiovascular disease education for pharmacists.  This ACPE Accredited course will expose pharmacists to didactic lectures on the treatment of cardiovascular illness from recognized authorities in cardiovascular research, education, prevention, and management.  The course format promotes discussion, questions, and participant/faculty interaction.  The comprehensive subject matter includes coronary artery disease, stroke, venous thromboembolism, law, and treatment of STEMI, presented by Elliott Antman, MD, of the Brigham and Women’s Hospital TIMI Research Group.  Break out session topics include heparin induced thrombocytopenia and treatment of hyponatremia.

References:

  1. Bhatt D, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PWF. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis.  JAMA. 2006; 295: 180-189.
  2. Yan LL, Lin K, Daviglus ML, Colangelo LA, Kiefe CI, Sidney S, Matthews KA, Greenland P. Education, 15-Year Risk Factor Progression, and Coronary Artery Calcium in Young Adulthood and Early Middle Age: The Coronary Artery Risk Development in Young Adults Study. JAMA. 2006; 295: 1793-1800.
  3. Goldhaber SZ, Morrison RB.  Pulmonary embolism and deep vein thrombosis.  Circulation 2002; 106:1436-1438.
  4. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL.Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166:955-64.
  5. Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E, Kachalia A, Horng M, Roy CL, McKean SC, Bates DW. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006;166:565-71.
  6. Smith WE. Role of a pharmacist in improving rational drug therapy as part of the patient care team. Ann Pharmacother. 2007 Feb;41(2):330-5.